Centessa Pharmaceuticals (NASDAQ:CNTA) Downgraded to “Hold” Rating by Stephens

Stephens cut shares of Centessa Pharmaceuticals (NASDAQ:CNTA) from a strong-buy rating to a hold rating in a research report report published on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. B. Riley Financial raised their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Oppenheimer boosted their price objective on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Truist Financial upped their price objective on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.00.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $39.72 on Tuesday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $40.26. The business has a fifty day moving average of $26.29 and a 200-day moving average of $25.24. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -21.70 and a beta of 1.55.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). As a group, analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the sale, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 349,073 shares of company stock worth $9,429,412 in the last three months. Company insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Millennium Management LLC grew its position in Centessa Pharmaceuticals by 52.9% during the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after acquiring an additional 210,737 shares during the period. Jane Street Group LLC purchased a new position in shares of Centessa Pharmaceuticals in the 1st quarter worth about $2,176,000. Geode Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 44.7% in the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock worth $1,149,000 after purchasing an additional 26,994 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Centessa Pharmaceuticals by 155.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after purchasing an additional 260,702 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Centessa Pharmaceuticals by 29.2% during the 2nd quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock worth $1,291,000 after purchasing an additional 22,205 shares during the period. 82.01% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep‑medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short‑term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near‑term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12‑month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.